LB PHARMACEUTICALS INC 8-K

What Happened

• LB Pharmaceuticals, Inc. (LBRX) announced on March 26, 2026 (via Form 8‑K, Item 2.02) that it issued a press release reporting its financial results for the three months and full year ended December 31, 2025. The press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: March 26, 2026 (Form 8‑K, Item 2.02).
• Periods covered: three months and full year ended December 31, 2025.
• Disclosure format: press release furnished as Exhibit 99.1; Inline XBRL cover page tags included in the filing.
• The 8‑K furnishes the results announcement but does not itself restate specific financial figures within the Form 8‑K text.

Why It Matters

• This filing signals that LBRX has released its quarterly and annual earnings information — a primary data point investors use to assess recent performance, revenue trends, and operating results.
• Investors should read the attached press release (Exhibit 99.1) and any accompanying financial statements or presentations for detailed revenue, net income, cash flow and management commentary, since the 8‑K indicates the results were announced but does not embed the numeric details in the filing text.
• Look for follow‑up filings (e.g., 10‑K or Form 8‑K amendments) for full audited financial statements or management discussion and analysis if you need audited numbers or forward guidance.